Select Language
Integrin alpha V beta 3
Integrin alpha V beta 3 Overview
| English Name | Integrin alpha-V/beta-3 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 29 | Target Synonym | Integrin alphaVbeta3 |
| Highest Development Stage | NDA/BLA | ||
| English Name | Integrin alpha-V/beta-3 |
| Target Synonym | Integrin alphaVbeta3 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 29 |
| Highest Development Stage | NDA/BLA |
Integrin alpha V beta 3 Product List
- Product Category
Protein (7)
- Product Status
Launched (7)
- Species
Human (2)Rat (1)Cynomolgus (2)Mouse (2)
- Tag
His Tag (4)His Tag & Avi Tag (3)
- Conjugate
Unconjugated (4)Biotin-labeled (3)
Total: 7
- 1
Integrin alpha V beta 3 Background
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Integrin alpha V beta 3 Synonyms
Integrin alpha V beta 3,ITGAV&ITGB3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alfatide[18F] | 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] | Phase 3 Clinical | Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Contrast agents; Head and Neck Neoplasms; Lung Neoplasms; Lymphoma; Neoplasms; Soft Tissue Neoplasms | Details |
| 18F-LNC1016 | 18F-LNC-1016; 18F-LNC1016 | Phase 3 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Lung Neoplasms | Details |
| 18F-LNC1007 | 18F-LNC1007; 18F-FAPI-RGD | Phase 3 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Carcinoma, Renal Cell; Diagnostic agents; Neoplasms; Solid tumours | Details |
| IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Idiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Nesvategrast | SF-0166; OTT-166(OcuTerra Therapeutics) | Phase 2 Clinical | OcuTerra Therapeutics Inc, Scifluor Life Sciences Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
| 68Ga-FAP-RGD | 68Ga-FAP-RGD | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | Details |
| 68Ga-HX01 | 68Ga-HX01; 68GaHX01 | Phase 2 Clinical | Hexin (Suzhou) Pharmaceutical Technology Co Ltd | Contrast agents; Neoplasms; Sarcoma; Solid tumours | Details |
| ProAgio | Phase 2 Clinical | National Cancer Institute | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details | |
| Ga-68 NODAGA-RGD | Theranost 68Ga-RGD; [68Ga]Theranost | Phase 1 Clinical | Advanced Imaging Projects, National Cancer Institute, Zentralklinik Bad Berka | Lung Neoplasms; Neovascularization, Pathologic | Details |
| Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration | Details |
| 68Ga-NOTA-BBN-RGD | 68Ga-NOTA-BBN-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms; Prostatic Neoplasms | Details |
| BGC-0222 | BGC0222; BGC-0222 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd, Gaorui Yaoye (Beijing) Technologies Co Ltd | Solid tumours | Details |
| Antiangiotide | HM-3; IIM-3 | Phase 1 Clinical | China Pharmaceutical University, Inner Mongolia Tianqi Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| 68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3P-TATE-RGD; 68Ga-NOTA-3PTATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Carcinoma, Neuroendocrine; Lung Neoplasms; Meningioma; Neuroendocrine Tumors | Details |
| 177Lu-FF-10158 | 177Lu-FF-10158 | Phase 1 Clinical | Fujifilm Holdings Corp | Glioblastoma | Details |
| Transferrin | OCU-200 | Phase 1 Clinical | Ocugen Inc | Diabetic macular oedema; Diabetic Retinopathy; Wet Macular Degeneration | Details |
| VIP-236 | VIP-236 | Phase 1 Clinical | Bayer AG | Neoplasms; Solid tumours | Details |
| 177Lu-HX02 | 177Lu-HX02; 177Lu-HX-02 | Phase 1 Clinical | Hexin (Suzhou) Pharmaceutical Technology Co Ltd | Neoplasms; Solid tumours | Details |
| 177Lu-FAPI-RGD | 177Lu-FAPI-RGD; [177Lu]-FAPI-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | Details |
| 177Lu-TATE-RGD | 177Lu-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | Details |
| 177Lu-LNC1009 | 177Lu-LNC1009; 177Lu-LNC-1009 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Solid tumours | Details |
| 177Lu-LNC1008 | 177Lu-LNC1008 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Solid tumours | Details |
| 68Ga-LNC-1007 | 68Ga-FAPI-RGD; 68Ga-LNC-1007 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Carcinoma, Renal Cell; Neoplasms | Details |
| NP-011 | NP-011 | Phase 1 Clinical | Nexell Therapeutics Inc | Myocardial Infarction | Details |
| (68)Ga-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Keloid | Details | |
| fb-PMT | NP-100; NP-751 | Phase 1 Clinical | NanoPharmaceuticals LLC | Glioma | Details |
| 177Lu-AB-3PRGD2 | 177Lu-AB-3PRGD2 | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms; Solid tumours | Details |
| Pagantangentide | Phase 1 Clinical | China Pharmaceutical University, Jiangsu Aotexin Biomedical Technology Co Ltd, Nanjing Anji Biological Technology Co Ltd | Arthritis, Rheumatoid; Rheumatic Diseases | Details | |
| Lutetium-177 EBRGD (Molecular Targeting Technologies) | 177Lu-EBRGD; Lu-177 EBRGD; 177Lu-EB-RGD | Clinical | National Institute Of Biomedical Innovation | Carcinoma, Non-Small-Cell Lung; Glioblastoma | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: